PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
12.55%
Some net income increase while TRAW is negative at -11.51%. John Neff would see a short-term edge over the struggling competitor.
-4.31%
Negative yoy D&A while TRAW is 25.00%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
-1173.94%
Negative yoy deferred tax while TRAW stands at 766.04%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
-7.99%
Negative yoy SBC while TRAW is 31.87%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
214.02%
Well above TRAW's 81.62% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-138.21%
Negative yoy AP while TRAW is 515.43%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
259.96%
Some yoy usage while TRAW is negative at -69.36%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
1173.94%
Some yoy increase while TRAW is negative at -766.04%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
18.46%
Operating cash flow growth above 1.5x TRAW's 0.47%. David Dodd would confirm superior cost control or stronger revenue-to-cash conversion.
36.17%
CapEx growth of 36.17% while TRAW is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
36.17%
We expand invests by 36.17% while TRAW is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.
No Data
No Data available this quarter, please select a different quarter.
-70.77%
Negative yoy issuance while TRAW is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.